Skip to main content
Explore URMC

menu

Paul M. Barr, M.D.

Cancer

Publications

Showing all 104 journal articles & 33 books available

Journal Articles

7/15/2019
Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR. "Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2019 Jul 15; 25(14):4264-4270. Epub 2019 Apr 19.

7/8/2019
Loh KP, Baran A, Lee CY, Alshaibani A, Rutherford SC, Hu J, Casulo C, Barr PM, Friedberg JW, Reagan PM. "Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation." Leukemia & lymphoma.. 2019 Jul 8; :1-4. Epub 2019 Jul 08.

7/2019
Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ. "Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States." British journal of haematology.. 2019 Jul 0; 186(2):255-262. Epub 2019 May 01.

6/25/2019
Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. "Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies." Blood advances.. 2019 Jun 25; 3(12):1799-1807.

5/28/2019
Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP. "A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL." Blood advances.. 2019 May 28; 3(10):1568-1573.

5/9/2019
Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. "Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab." Blood.. 2019 May 9; 133(19):2031-2042. Epub 2019 Mar 06.

3/28/2019
Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC. "Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy." Haematologica.. 2019 Mar 28; Epub 2019 Mar 28.

2/14/2019
O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA. "Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with CLL: phase 3 analysis." American journal of hematology.. 2019 Feb 14; Epub 2019 Feb 14.

2/10/2019
Burger JA, Cramer P, Barr PM, Dilhuydy MS, Mato A, Byrd JC, Chang S, Graef T, Lin T, Tedeschi A. "Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies." British journal of haematology.. 2019 Feb 10; Epub 2019 Feb 10.

2/10/2019
Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. "Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia." British journal of haematology.. 2019 Feb 10; Epub 2019 Feb 10.

1/30/2019
"How I treat early relapsing follicular lymphoma." Blood.. 2019 Jan 30; Epub 2019 Jan 30.

12/1/2018
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC. "Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL." The New England journal of medicine.. 2018 Dec 1; Epub 2018 Dec 01.

11/27/2018
Wierda WG, Byrd JC, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H, Heffner L, Zhou L, Verdugo M, Potluri J, Choi M. "Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor." British journal of haematology.. 2018 Nov 27; Epub 2018 Nov 27.

11/2018
Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P. "Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies." American journal of hematology.. 2018 Nov 0; 93(11):1402-1410. Epub 2018 Oct 09.

11/2018
Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C. "Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial." American journal of hematology.. 2018 Nov 0; 93(11):1394-1401. Epub 2018 Sep 26.

10/13/2018
Williams AM, Baran AM, Casulo C, Reagan P, Friedberg JW, Helber M, Moore J, Baloga E, Zent CS, Barr PM. "Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience." Clinical lymphoma, myeloma & leukemia.. 2018 Oct 13; Epub 2018 Oct 13.

10/2018
O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R. "Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma." Clinical lymphoma, myeloma & leukemia.. 2018 Oct 0; 18(10):648-657.e15. Epub 2018 Jun 28.

10/2018
VanDerMeid KR, Elliott MR, Baran AM, Barr PM, Chu CC, Zent CS. "Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies." Cancer immunology research.. 2018 Oct 0; 6(10):1150-1160. Epub 2018 Aug 08.

9/2018
Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P. "Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2." Haematologica.. 2018 Sep 0; 103(9):1502-1510. Epub 2018 Jun 07.

9/2018
Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C. "Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States." Haematologica.. 2018 Sep 0; 103(9):1511-1517. Epub 2018 Jun 07.

8/29/2018
David RJ, Baran A, Loh KP, Casulo C, Barr PM, Friedberg JW, Reagan PM. "Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma." Clinical lymphoma, myeloma & leukemia.. 2018 Aug 29; Epub 2018 Aug 29.

8/22/2018
Phillips T, Barr PM, Park SI, Kolibaba K, Caimi PF, Chhabra S, Kingsley EC, Boyd T, Chen R, Carret AS, Gartner EM, Li H, Yu C, Smith DC. "A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma." Investigational new drugs.. 2018 Aug 22; Epub 2018 Aug 22.

8/15/2018
Barr PM. "Counterpoint: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?" Oncology.. 2018 Aug 15; 32(8):404, 407-9.

8/2018
Persky DO, Li H, Rimsza LM, Barr PM, Popplewell LL, Bane CL, Von Gehr A, LeBlanc M, Fisher RI, Smith SM, Friedberg JW. "A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806." American journal of hematology.. 2018 Aug 0; 93(4):486-493. Epub 2018 Jan 25.

8/2018
Archibald WJ, Meacham PJ, Williams AM, Baran AM, Victor AI, Barr PM, Sahasrahbudhe DM, Zent CS. "Management of melanoma in patients with chronic lymphocytic leukemia." Leukemia research.. 2018 Aug 0; 71:43-46. Epub 2018 Jul 06.

7/19/2018
Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, Zhou L, Scherle P, Chen X, Barr PM. "Phase 1 study of the PI3K? inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma." Blood.. 2018 Jul 19; 132(3):293-306. Epub 2018 Apr 25.

6/2018
Coutre S, Tedeschi A, Robak T, Barr PM, Owen C, Bairey O, Burger J, Zhou C, Styles L, James DF, Kipps TJ. "Survival adjusting for crossover: phase 3 study of ibrutinib . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma." Haematologica.. 2018 Jun 0; 103(6):e249-e251. Epub 2017 Nov 23.

5/28/2018
Rodgers TD, Barr PM. "Pitfalls of Combining Novel Agents in Lymphoma." Current treatment options in oncology.. 2018 May 28; 19(7):35. Epub 2018 May 28.

5/2018
Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, Howlett C, Skarbnik A, Cheson BD, Zent C, Pu J, Kiselev P, Goy A, Claxton D, Isaack K, Kennard KH, Timlin C, Landsburg D, Winter A, Nasta SD, Bachow SH, Schuster SJ, Dorsey C, Svoboda J, Barr P, Ujjani CS. "Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis." Haematologica.. 2018 May 0; 103(5):874-879. Epub 2018 Feb 01.

3/2018
Williams AM, Baran AM, Meacham PJ, Feldman MM, Valencia HE, Newsom-Stewart C, Gupta N, Janelsins MC, Barr PM, Zent CS. "Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies." Leukemia & lymphoma.. 2018 Mar 0; 59(3):625-632. Epub 2017 Jul 11.

3/2018
Barr PM, Li H, Burack WR, LeBlanc M, Smith SM, Gopal AK, Floyd JD, Persky DO, Press OW, Fisher RI, Friedberg JW. "R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study." The Lancet. Haematology.. 2018 Mar 0; 5(3):e102-e108. Epub 2018 Jan 26.

1/2018
Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC. "Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL." Leukemia.. 2018 Jan 0; 32(1):83-91. Epub 2017 Jun 08.

1/2018
Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC. "Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial." The Lancet. Oncology.. 2018 Jan 0; 19(1):65-75. Epub 2017 Dec 12.

10/3/2017
Caimi PF, Cooper BW, William BM, Dowlati A, Barr PM, Fu P, Pink J, Xu Y, Lazarus HM, de Lima M, Gerson SL. "Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies." Oncotarget.. 2017 Oct 3; 8(45):79864-79875. Epub 2017 Aug 09.

9/1/2017
Dabaja BS, Zelenetz AD, Ng AK, Tsang RW, Qi S, Allen PK, Hodgson D, Ricardi U, Hoppe RT, Advani R, Mauch PM, Constine LS, Specht L, Li Y, Terezakis SA, Wirth A, Reinartz G, Eich HT, Aleman BMP, Barr P, Yahalom J. "Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)." Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Sep 1; 28(9):2185-2190.

9/2017
Rowswell-Turner RB, Barr PM. "Treatment of chronic lymphocytic leukemia in older adults." Journal of geriatric oncology.. 2017 Sep 0; 8(5):315-319. Epub 2017 May 06.

7/2017
Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM. "Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib." British journal of haematology.. 2017 Jul 0; 178(2):286-291. Epub 2017 Apr 10.

6/1/2017
Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, Koh B, Ye W, Barr PM, Salles GA, Friedberg JW. "Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy." Blood.. 2017 Jun 1; 129(22):3037-3039. Epub 2017 Mar 21.

6/2017
Martin P, Barr PM, James L, Pathak A, Kahl B. "Long-term safety experience with bendamustine for injection in a real-world setting." Expert opinion on drug safety.. 2017 Jun 0; 16(6):647-650. Epub 2017 Apr 17.

5/11/2017
Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC. "Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL." Blood.. 2017 May 11; 129(19):2612-2615. Epub 2017 Apr 03.

5/1/2017
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. "Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients." Annals of oncology : official journal of the European Society for Medical Oncology. 2017 May 1; 28(5):1050-1056.

5/2017
Jaffe ES, Barr PM, Smith SM. "Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice." American Society of Clinical Oncology educational book. 2017 May 0; (37):535-546.

4/20/2017
Barr PM. "Efficacy in the margins of NHL with ibrutinib." Blood.. 2017 Apr 20; 129(16):2207-2208.

4/2017
Reagan PM, Barr PM. "Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve." The Lancet. Haematology.. 2017 Apr 0; 4(4):e152-e153. Epub 2017 Mar 15.

3/2017
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. "RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106." British journal of haematology.. 2017 Mar 0; 176(5):759-769. Epub 2016 Dec 19.

3/2017
Hunter BD, Herr M, Meacham PJ, Barlaskar F, Evans AG, Burack WR, Liesveld JL, Becker MW, Milner LA, Constine LS, Dhakal S, Barr PM, Friedberg JW, Casulo C. "Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era." Clinical lymphoma, myeloma & leukemia.. 2017 Mar 0; 17(3):145-151. Epub 2016 Nov 23.

3/2017
Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM. "Recommendations for Clinical Trial Development in Follicular Lymphoma." Journal of the National Cancer Institute.. 2017 Mar 0; 109(3)Epub 2016 Dec 31.

1/27/2017
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. "Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients." Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Jan 27; Epub 2017 Jan 27.

1/25/2017
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. "Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients." Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Jan 25; Epub 2017 Jan 25.

2017
Jaffe ES, Barr PM, Smith SM. "Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice." American Society of Clinical Oncology educational book. 2017 37:535-546.

12/8/2016
Barr PM. "Deregulation of NF-?B, ie, a useful PMBL marker." Blood.. 2016 Dec 8; 128(23):2591-2592.

11/3/2016
Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM. "Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience." Blood.. 2016 Nov 3; 128(18):2199-2205. Epub 2016 Sep 06.

11/2016
Reid RM, Baran A, Friedberg JW, Phillips GL, Liesveld JL, Becker MW, Wedow L, Barr PM, Milner LA. "Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective." Cancer medicine. 2016 Nov 0; 5(11):3059-3067. Epub 2016 Oct 03.

10/1/2016
Youn P, Cummings MA, Dhakal S, Burack WR, Casulo C, Barr PM, Friedberg JW, Constine LS. "Prognostic Impact of Cell of Origin in Limited-Stage Diffuse Large B-Cell Lymphoma Treated With R-CHOP With or Without Radiation Therapy." International journal of radiation oncology, biology, physics.. 2016 Oct 1; 96(2S):E495.

9/15/2016
Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH. "Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma." Blood.. 2016 Sep 15; 128(11):1458-64. Epub 2016 Jul 25.

9/2016
Herr MM, Mohile NA, Barr PM, van Wijngaarden E, Brown EB, Rich DQ. "Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era." Clinical lymphoma, myeloma & leukemia.. 2016 Sep 0; 16(9):e123-e127. Epub 2016 Jun 08.

8/25/2016
Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, Weinstock DM, Weigert O. "Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy." Blood.. 2016 Aug 25; 128(8):1112-20. Epub 2016 Jul 14.

7/2016
Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ. "Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia." Haematologica.. 2016 Jul 0; 101(7):e295-8. Epub 2016 May 05.

6/10/2016
Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. "US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 Jun 10; 34(17):2020-7. Epub 2016 Apr 11.

6/2016
Reagan PM, Baran A, Kelly JL, Barr PM, Casulo C, Chengazi VU, Friedberg JW. "Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma." Clinical lymphoma, myeloma & leukemia.. 2016 Jun 0; 16(6):322-328.e2. Epub 2016 Apr 02.

5/19/2016
Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O'Brien SM, Liem AK, McIntyre RE, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, He J, Hu J, Dreiling LK, Friedberg JW. "Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL." Blood.. 2016 May 19; 127(20):2411-5. Epub 2016 Mar 11.

3/24/2016
Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA. "Postibrutinib outcomes in patients with mantle cell lymphoma." Blood.. 2016 Mar 24; 127(12):1559-63. Epub 2016 Jan 13.

2016
Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW. "Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas." Leukemia & lymphoma.. 2016 57(3):635-43. Epub 2015 Oct 12.

12/17/2015
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ, . "Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia." The New England journal of medicine.. 2015 Dec 17; 373(25):2425-37. Epub 2015 Dec 06.

12/2015
Choudary I, Barr PM, Friedberg J. "Recent advances in the development of Aurora kinases inhibitors in hematological malignancies." Therapeutic advances in hematology.. 2015 Dec 0; 6(6):282-94.

8/2015
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. "Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma." Nature medicine.. 2015 Aug 0; 21(8):922-6. Epub 2015 Jul 20.

7/20/2015
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. "Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015 Jul 20; 33(21):2399-404. Epub 2015 Jun 15.

5/7/2015
Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S. "The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia." Blood.. 2015 May 7; 125(19):2915-22. Epub 2015 Mar 09.

3/2015
Barr PM. "Rituximab maintenance in follicular lymphoma." Clinical advances in hematology & oncology : H&O.. 2015 Mar 0; 13(3):158-61.

2/2015
Hutchinson K, Jahangiri S, Calvi LM, Barr P, Friedberg JW, Kelly JL. "Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma." Leukemia & lymphoma.. 2015 Feb 0; 56(2):508-11. Epub 2014 Jul 15.

12/2014
Barr PM, Zent CS. "Infection in chronic lymphocytic leukemia: parsimony has its limits." Leukemia & lymphoma.. 2014 Dec 0; 55(12):2683-4. Epub 2014 May 16.

9/2014
Jahangiri S, Barr P, Friedberg J. "Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma." Expert opinion on emerging drugs.. 2014 Sep 0; 19(3):367-83. Epub 2014 Jun 24.

8/21/2014
Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM. "Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma." Blood.. 2014 Aug 21; 124(8):1259-65. Epub 2014 Jul 11.

8/2014
Barr PM. "Maintenance rituximab should be considered for patients with follicular lymphoma." Clinical advances in hematology & oncology : H&O.. 2014 Aug 0; 12(8):541-3.

7/17/2014
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P, . "Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia." The New England journal of medicine.. 2014 Jul 17; 371(3):213-23. Epub 2014 May 31.

7/2014
Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI. "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma." Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Jul 0; 25(7):1449.

6/20/2014
Brown JR, O'Brien SM, Barrientos JC, Kay NE, Reddy NM, Coutre SE, Tam C, Mulligan SP, Jäger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Fardis M, McGreivy JS, Clow F, James DF, Hillmen P. "Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2014 Jun 20; 32(18_suppl):LBA7008.

6/2014
Barr PM, Zent CS. "The ABC of chronic lymphocytic leukemia: etiology of cytopenias is important in staging and management." Leukemia & lymphoma.. 2014 Jun 0; 55(6):1219-20. Epub 2013 Nov 01.

3/1/2014
Cleary JM, Rodig S, Barr PM, Shinagare AB, Clark JW, Shapiro GI, Armand P. "Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma." Journal of the National Comprehensive Cancer Network : JNCCN.. 2014 Mar 1; 12(3):323-6; quiz 326.

12/2013
Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI. "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma." Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Dec 0; 24(12):3076-81. Epub 2013 Oct 20.

10/2013
Barr PM. "Flavopiridol: Judged by the company one keeps." Leukemia research.. 2013 Oct 0; 37(10):1187-8. Epub 2013 Jul 08.

8/2013
Herman SE, Barr PM, McAuley EM, Liu D, Wiestner A, Friedberg JW. "Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia." Leukemia.. 2013 Aug 0; 27(8):1769-73. Epub 2013 Feb 06.

2/2013
Barr PM. "Fffuse large B-cell lymphoma in the very elderly: the case for refining our clinical trials." Oncology.. 2013 Feb 0; 27(2):140, 142.

12/2012
Bayraktar UD, Ramos JC, Petrich A, Gupta N, Lensing S, Moore P, Reid EG, Aboulafia DM, Ratner L, Mitsuyasu R, Cooley T, Henry DH, Barr P, Noy A. "Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium." Leukemia & lymphoma.. 2012 Dec 0; 53(12):2383-9. Epub 2012 Jul 09.

7/2012
Kindwall-Keller TL, Hegerfeldt Y, Meyerson HJ, Margevicius S, Fu P, van Heeckeren W, Lazarus HM, Cooper BW, Gerson SL, Barr P, Tse WW, Curtis C, Fanning LR, Creger RJ, Carlson-Barko JM, Laughlin MJ. "Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies." Bone marrow transplantation.. 2012 Jul 0; 47(7):924-33. Epub 2011 Oct 17.

6/2012
Noel MS, Friedberg JW, Barr PM. "Novel agents in mantle cell lymphoma." Best practice & research. Clinical haematology.. 2012 Jun 0; 25(2):191-200. Epub 2012 Apr 30.

3/2012
Barr PM, Wei C, Roger J, Schaefer-Cutillo J, Kelly JL, Rosenberg AF, Jung J, Sanz I, Friedberg JW. "Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion." Clinical immunology : the official journal of the Clinical Immunology Society.. 2012 Mar 0; 142(3):237-42. Epub 2012 Jan 05.

2012
Caimi PF, Barr PM, Berger NA, Lazarus HM. "Non-Hodgkin's Lymphoma in the Elderly". Drugs & Aging. 2012; 27(3): 211-238.

2012
Noel, MS; Friedberg, JW; Barr, PM;. "Novel agents in mantle cell lymphoma". Best Practices & Resaerch Clinical Haematology. 2012; 25(2): 191-200.

11/2011
Carter SJ, Bernstein SH, Friedberg JW, Barr PM. "Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma." Leukemia research.. 2011 Nov 0; 35(11):e223-4. Epub 2011 Aug 06.

7/2011
Lazarus HM, Sommers SR, Arfons LM, Fu P, Ataergin SA, Kaye NM, Liu F, Kindwall-Keller TL, Cooper BW, Laughlin MJ, Creger RJ, Barr PM, Gerson SL, Kaplan D. "Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2011 Jul 0; 17(7):970-8. Epub 2011 Apr 11.

7/2011
Barr PM, Friedberg JW. "Getting to the heart of the problem in treating diffuse large B-cell lymphoma." Leukemia & lymphoma.. 2011 Jul 0; 52(7):1166-7. Epub 2011 May 25.

6/2011
Dao H, Barr PM, Honda K. "Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox." Journal of the American Academy of Dermatology.. 2011 Jun 0; 64(6):e123-5.

9/2010
Harr MW, Caimi PF, McColl KS, Zhong F, Patel SN, Barr PM, Distelhorst CW. "Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia." Cell death and differentiation.. 2010 Sep 0; 17(9):1381-91. Epub 2010 Mar 19.

3/1/2010
Caimi PF, Barr PM, Berger NA, Lazarus HM. "Non-Hodgkin's lymphoma in the elderly." Drugs & aging.. 2010 Mar 1; 27(3):211-38.

3/2010
Kaplan D, Meyerson HJ, Li X, Drasny C, Liu F, Costaldi M, Barr P, Lazarus HM. "Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL." Cytometry. Part B, Clinical cytometry.. 2010 Mar 0; 78(2):115-22.

10/2009
Barr PM, Fu P, Lazarus HM, Horvath N, Gerson SL, Koc ON, Bahlis NJ, Snell MR, Dowlati A, Cooper BW. "Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma." British journal of haematology.. 2009 Oct 0; 147(1):89-96. Epub 2009 Jun 29.

8/2009
Barr PM, Lazarus HM, Cooper BW, Schluchter MD, Panneerselvam A, Jacobberger JW, Hsu JW, Janakiraman N, Simic A, Dowlati A, Remick SC. "Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant." American journal of hematology.. 2009 Aug 0; 84(8):484-7.

6/2009
Rong YP, Barr P, Yee VC, Distelhorst CW. "Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor." Biochimica et biophysica acta.. 2009 Jun 0; 1793(6):971-8. Epub 2008 Nov 12.

9/2008
Barr PM, Lazarus HM. "Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation." Current opinion in oncology.. 2008 Sep 0; 20(5):502-8.

12/2007
Barr P, Fisher R, Friedberg J. "The role of bortezomib in the treatment of lymphoma." Cancer investigation.. 2007 Dec 0; 25(8):766-75.

10/2007
Barr P, Fu P, Lazarus H, Kane D, Meyerson H, Hartman P, Reyes R, Creger R, Stear K, Laughlin M, Tse W, Cooper B. "Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia." Leukemia & lymphoma.. 2007 Oct 0; 48(10):1940-9.

7/18/1997
Malinowski MN, Cannady SB, Schmit KV, Barr PM, Schrock JW, Wilson DF. "Adenosine depresses transmitter release but is not the basis for 'tetanic fade' at the neuromuscular junction of the rat." Neuroscience letters.. 1997 Jul 18; 230(2):81-4.

Barr PM, Zent CS. "The ABC of chronic lymphocytic leukemia: Etiology of cytopenias is important in staging and management". Leukemia Lymphoma [EPub in press]. .

Books & Chapters

2019
Book Title: How I treat early relapsing follicular lymphoma
Author List: Casulo C, Barr PM
Published By: Blood2019

2019
Book Title: Augmenting Indolent Lymphoma Treatment Options with the Combination of Lenalidomide and Rituximab.
Author List: Barr PM
Published By: J Clin Oncology2019

2018
Book Title: COUNTERPOINT: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?
Author List: Barr PM
Published By: Oncology2018

2018
Book Title: Pitfalls of Combining Novel Agents in Lymphoma
Author List: Rodgers TD; Barr PM
Published By: Current treatment options in oncology2018

2017
Book Title: Rare B Cell Lymphoproliferative Disorders. In: Textbook of Uncommon Cancers
Author List: Evans AG, Barr PM
Published By: Wiley-Blackwell, Oxford, England2017

2017
Book Title: Treatment of Chronic Lymphocytic Leukemia in Older Adults
Author List: Rowswell-Turner R, Barr PM
Published By: Journal of Geriatric Oncology2017

2017
Book Title: Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice
Author List: Jaffe ES; Barr PM; Smith SM
Published By: American Society of Clinical Oncology educational book2017

2017
Book Title: Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve
Author List: Reagan PM, Barr PM
Published By: Lancet Haematol2017

2017
Book Title: Efficacy in the margins of NHL with ibrutinib
Author List: Barr PM
Published By: Blood2017

2016
Book Title: Deregulation of NF-kB, ie, a useful PMBL marker
Author List: Barr PM
Published By: Blood2016

2015
Book Title: Rituximab maintenance in follicular lymphoma
Author List: Barr PM
Published By: Clinical advances in hematology & oncology2015

2015
Book Title: Recent advances in the development of Aurora kinase inhibitors in hematological malignancies
Author List: Choudary I, Barr PM, Friedberg J.
Published By: Therapeutic advances in hematology2015

2014
Book Title: The ABC of CLL: Etiology of Cytopenias is Important in Staging and Management
Author List: Barr PM, Zent CS
Published By: Leukemia & Lymphoma2014

2014
Book Title: Adult Burkitt Lymphoma and Leukemia. In: Rare Lymphomas
Author List: Gokbuget N, Barr PM, Friedberg JW, Hsi ED, Ott G
Published By: Dreyling M, (eds). Springer-Verlag Berlin Heidelberg, New York2014

2014
Book Title: Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma
Author List: Jahangiri S, Friedberg J, Barr PM
Published By: Expert opinion on emerging drugs2014

2014
Book Title: Attempting to avoid chemotherapy in CLL with lenalidomide and rituximab
Author List: Barr PM
Published By: doi: 10.1200/JCO.2013.51.58902014

2014
Book Title: Infection in chronic lymphocytic leukemia: parsimony has its limits
Author List: Barr PM, Zent CS
Published By: Leukemia & Lymphoma2014

2014
Book Title: Maintenance rituximab should be considered for patients with follicular lymphoma.
Author List: Barr PM
Published By: Clinical advances in hematology & oncology2014

2013
Book Title: Neoplastic Diseases of the Blood
Author List: Barr PM
Published By: 5th edition. Leukemia Research2013

2013
Book Title: Diffuse Large B-Cell Lymphoma in the Very Elderly: The Case for Refining Our Clinical Trials.
Author List: Barr PM
Published By: Oncology2013

2013
Book Title: Flavopiridol: Judged by the company ones keeps
Author List: Barr PM
Published By: Leukemia Research2013

2013
Book Title: Clinical evaluation and management of Burkitt Lymphoma
Author List: Barr PM, Friedberg JW
Published By: Clinical Decision Support in Hematology2013

2012
Book Title: Novel agents in mantle cell lymphoma
Author List: Noel MS, Friedberg JW, Barr PM
Published By: Best Practice & Research Clinical Haematology2012

2012
Book Title: Rare B Cell Lymphoproliferative Disorders. In: Textbook of Uncommon Cancers
Author List: Barr PM, Friedberg JW
Published By: 4th edition. Sekkeres MA, (eds). Wiley-Blackwell, Oxford, England2012

2012
Chapter Title: Rare B Cell Lymphoproliferative Disorders
Book Title: Textbook of Uncommon Cancers
Author List: Barr PM and Friedberg JW
Published By: Wiley-Blackwell2012 in Oxford, England

2011
Book Title: Getting to the heart of the problem in treating diffuse large B-cell lymphoma
Author List: Barr PM, Friedberg JW
Published By: Leuklemia and Lymphoma2011

2010
Chapter Title: Pharmacology of Acute Lymphoblastic Leukemia Therapy
Book Title: Adult Acute Lymphocytic Leukemia: Biology and Treatment
Author List: Barr PM, Creger RJ, Berger NA
Published By: Humana Press2010

2010
Book Title: Non-Hodgkin's Lymphoma in the Elderly
Author List: Caimi PF, Barr PM, Berger NA, Lazarus HM
Published By: Drugs & Aging2010

2009
Book Title: Non-Hodgkin Lymphoma. In: Clinical Care Options inPractice
Author List: Barr PM and Fisher RI
Published By: Govindan R, Kantarjian H.(eds2009

2008
Book Title: Non-Hodgkin lymphomas
Author List: Devita VT, Lawrence TS, Rosenberg SA editors
Published By: In Cancer, Principles & Practice of Oncology 9th edition2008

2008
Book Title: Non-Hodgkin lymphomas
Author List: Devita VT, Lawrence TS, Rosenberg SA
Edited By: Lippincott Williams & Wilkins
Published By: Cancer, Principles & Practice of Oncology 10th edition2008

2008
Book Title: Follicular non-Hodgkin lymphoma: long term results of stem cell transplantation
Author List: Barr PM, Lazarus, HM
Published By: Current Opinion in Oncology2008

2007
Book Title: Role of Bortezomib in the Treatment of Lymphoma
Author List: Barr PM, Fisher RI and Friedberg JW.
Published By: Cancer Investigation2007